CXS 0.00% 70.0¢ chemgenex pharmaceuticals ltd

three big announcements

  1. 1,521 Posts.
    lightbulb Created with Sketch. 3
    The first, reporting the updated data from patients who have multiple TKI therapies, made that additional indication much more likely, which adds to the medium-term prospects for OmaPro.

    The second, reporting the European deal with Hospira, was perhaps the biggest. If they had failed to negotiate a good enough European partnership, Chemgenex wouldn't have had the funding to market and distribute OmaPro in the US.

    The third, reporting the ODAC meeting, suggests that the FDA orphan drug approval process is proceding normally.

    These three announcements significantly raise my valuation of Chemgenex, and reduce its risk envelope. As a long-term investor I'm not too fussed about the share price, but it seems odd that it's in much the same place it was two weeks ago.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.